{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:20:48Z","timestamp":1788481248782,"version":"build-2803163510"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010643","name":"Cidara Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010643","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013075","name":"Mundipharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Rezafungin is approved for use in adults with candidemia and\/or invasive candidiasis (IC) based on data from the ReSTORE trial (NCT03667690), which demonstrated noninferior efficacy to caspofungin. For regulatory purposes, an additional cohort of patients from China was recruited to ReSTORE. Here, we compared rezafungin and caspofungin in patients with candidemia and\/or IC through analysis of the ReSTORE global data plus the China extension study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Adults with candidemia\/IC were randomized (1:1) to receive weekly rezafungin (400\/200\u2005mg) or daily caspofungin (70\/50\u2005mg) for \u226428 days. Noninferiority was concluded for primary efficacy endpoints if the upper bound of the 95% confidence interval (CI) was below 20% for Day 30 all-cause mortality and if the weighted lower bound was above \u221220% for Day 14 global cure. Additional efficacy outcomes and safety were evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 246 patients were randomized (122 rezafungin and 124 caspofungin). Noninferiority was demonstrated for both primary endpoints. Day 30 all-cause mortality was 25.2% and 24.8% (treatment difference 0.4%; 95% CI \u221210.8, 11.6) and Day 14 global cure was 56.5% and 57.3% (weighted treatment difference \u22121.0%; 95% CI \u221213.5, 11.6) with rezafungin versus caspofungin, respectively. Day 5 mycological eradication was numerically higher (68.7% vs 63.2%) and time to negative blood culture was numerically shorter (median 26.5 vs 38.8\u2005h). Safety was comparable between groups; 53.3% (64\/120; rezafungin) and 53.7% (66\/123; caspofungin) of patients experienced serious adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This analysis confirmed the overall efficacy and safety of rezafungin demonstrated in ReSTORE, with early efficacy related to front-loaded exposure.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofaf555","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T19:56:17Z","timestamp":1758311777000},"source":"Crossref","is-referenced-by-count":5,"title":["Rezafungin Versus Caspofungin for the Treatment of Candidemia and Invasive Candidiasis: Results from the Double-blind, Randomized, Phase 3 ReSTORE Trial Including the China Extension Study"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8518-5750","authenticated-orcid":false,"given":"George R","family":"Thompson","sequence":"first","affiliation":[{"name":"University of California Davis Medical Center , Sacramento, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihui","family":"Huang","sequence":"additional","affiliation":[{"name":"Institute of Antibiotics, Huashan Hospital, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sizhou","family":"Feng","sequence":"additional","affiliation":[{"name":"Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Tianjin ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2903-918X","authenticated-orcid":false,"given":"Yunsong","family":"Yu","sequence":"additional","affiliation":[{"name":"Sir Run Run Shaw Hospital of Zhejiang University School of Medicine , Hangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9374-0811","authenticated-orcid":false,"given":"Alex","family":"Soriano","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic de Barcelona, IDIBAPS, University of Barcelona, CIBERINF , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9599-3137","authenticated-orcid":false,"given":"Oliver A","family":"Cornely","sequence":"additional","affiliation":[{"name":"University of Cologne, and University Hospital Cologne, and German Centre for Infection Research (DZIF) , Cologne ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6813-8167","authenticated-orcid":false,"given":"Bart Jan","family":"Kullberg","sequence":"additional","affiliation":[{"name":"Radboudumc Center of Infectious Diseases and Radboud University Medical Center , Nijmegen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G","family":"Pappas","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham , Birmingham, Alabama ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marin","family":"Kollef","sequence":"additional","affiliation":[{"name":"Washington University , St. Louis, Missouri ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A","family":"Vazquez","sequence":"additional","affiliation":[{"name":"Medical College of Georgia\/Augusta University , Augusta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M","family":"Honore","sequence":"additional","affiliation":[{"name":"CHU UCL Godinne Namur, UCL Louvain Medical School , Namur ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cox","sequence":"additional","affiliation":[{"name":"Mundipharma Research Limited , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0145-9740","authenticated-orcid":false,"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[{"name":"University of Genoa and Policlinico San Martino IRCCS Hospital , Genoa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"2025092508515641200_ofaf555-B1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.cmi.2019.04.024","article-title":"Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis","volume":"25","author":"Koehler","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2025092508515641200_ofaf555-B2","doi-asserted-by":"crossref","first-page":"18026","DOI":"10.1038\/nrdp.2018.26","article-title":"Invasive candidiasis","volume":"4","author":"Pappas","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2025092508515641200_ofaf555-B3","doi-asserted-by":"crossref","first-page":"106229","DOI":"10.1016\/j.jinf.2024.106229","article-title":"Attributable mortality of candidemia\u2014results from the ECMM Candida III multinational European Observational Cohort Study","volume":"89","author":"Salmanton-Garc\u00eda","year":"2024","journal-title":"J Infect"},{"key":"2025092508515641200_ofaf555-B4","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/jac\/dkad139","article-title":"Invasive candidiasis: current clinical challenges and unmet needs in adult populations","volume":"78","author":"Soriano","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2025092508515641200_ofaf555-B5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.idc.2015.10.013","article-title":"Invasive candidiasis","volume":"30","author":"McCarty","year":"2016","journal-title":"Infect Dis Clin North Am"},{"key":"2025092508515641200_ofaf555-B6","doi-asserted-by":"crossref","first-page":"e449","DOI":"10.1093\/cid\/ciaa193","article-title":"Burden of candidemia in the United States, 2017","volume":"71","author":"Tsay","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025092508515641200_ofaf555-B7","author":"U.S. Centers for Disease Control and Prevention"},{"key":"2025092508515641200_ofaf555-B8","author":"UK Health Security Agency"},{"key":"2025092508515641200_ofaf555-B9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13756-020-00798-3","article-title":"A seven-year surveillance study of the epidemiology, antifungal susceptibility, risk factors and mortality of candidaemia among paediatric and adult inpatients in a tertiary teaching hospital in China","volume":"9","author":"Zeng","year":"2020","journal-title":"Antimicrob Resist Infect Control"},{"key":"2025092508515641200_ofaf555-B10","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/infdis\/jiaa502","article-title":"Invasive candidiasis species distribution and trends, United States, 2009\u20132017","volume":"223","author":"Ricotta","year":"2021","journal-title":"J Infect Dis"},{"key":"2025092508515641200_ofaf555-B11","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13054-019-2497-3","article-title":"Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project","volume":"23","author":"Bassetti","year":"2019","journal-title":"Crit Care"},{"issue":"Suppl 7","key":"2025092508515641200_ofaf555-B12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients","volume":"18","author":"Cornely","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2025092508515641200_ofaf555-B13","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2025092508515641200_ofaf555-B14","first-page":"29","article-title":"Chinese consensus on the diagnosis and management of adult candidiasis","volume":"38","author":"Guiqiang","year":"2020","journal-title":"Chin J Infect Dis"},{"key":"2025092508515641200_ofaf555-B15","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1016\/S1473-3099(24)00749-7","article-title":"Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM","volume":"25","author":"Cornely","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2025092508515641200_ofaf555-B16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13054-022-03892-7","article-title":"Association between hospital and ICU structural factors and patient outcomes in China: a secondary analysis of the National Clinical Improvement System Data in 2019","volume":"26","author":"Li","year":"2022","journal-title":"Crit Care"},{"key":"2025092508515641200_ofaf555-B17","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1080\/14756366.2022.2050224","article-title":"Echinocandins\u2014structure, mechanism of action and use in antifungal therapy","volume":"37","author":"Szyma\u0144ski","year":"2022","journal-title":"J Enzyme Inhib Med Chem"},{"key":"2025092508515641200_ofaf555-B18","doi-asserted-by":"crossref","first-page":"myad127","DOI":"10.1093\/mmy\/myad127","article-title":"Review of treatment options for a multidrug-resistant fungus: Candida auris","volume":"62","author":"Wang","year":"2024","journal-title":"Med Mycol"},{"key":"2025092508515641200_ofaf555-B19","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/21505594.2022.2054120","article-title":"Candida auris infections in China","volume":"13","author":"Du","year":"2022","journal-title":"Virulence"},{"key":"2025092508515641200_ofaf555-B20","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1080\/21505594.2022.2123325","article-title":"Distribution and antifungal susceptibility pattern of Candida species from mainland China: a systematic analysis","volume":"13","author":"Bilal","year":"2022","journal-title":"Virulence"},{"key":"2025092508515641200_ofaf555-B21","author":"Mundipharma GmbH"},{"key":"2025092508515641200_ofaf555-B22","author":"Melinta Therapeutics LLC"},{"key":"2025092508515641200_ofaf555-B23","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1093\/jac\/dkw214","article-title":"Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates","volume":"71","author":"Pfaller","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2025092508515641200_ofaf555-B24","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3390\/jof6040262","article-title":"Rezafungin-mechanisms of action, susceptibility and resistance: similarities and differences with the other echinocandins","volume":"6","author":"Garcia-Effron","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2025092508515641200_ofaf555-B25","doi-asserted-by":"crossref","first-page":"6872","DOI":"10.1128\/AAC.00701-16","article-title":"Preclinical evaluation of the stability, safety, and efficacy of CD101, a novel echinocandin","volume":"60","author":"Ong","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2025092508515641200_ofaf555-B26","doi-asserted-by":"crossref","first-page":"e0139021","DOI":"10.1128\/AAC.01390-21","article-title":"Metabolism, excretion, and mass balance of [(14)C]-rezafungin in animals and humans","volume":"66","author":"Ong","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2025092508515641200_ofaf555-B27","doi-asserted-by":"crossref","first-page":"e3647","DOI":"10.1093\/cid\/ciaa1380","article-title":"Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial","volume":"73","author":"Thompson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025092508515641200_ofaf555-B28","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","article-title":"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial","volume":"401","author":"Thompson","year":"2023","journal-title":"Lancet"},{"key":"2025092508515641200_ofaf555-B29","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1473-3099(23)00551-0","article-title":"Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials","volume":"24","author":"Thompson","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025092508515641200_ofaf555-B30","article-title":"Efficacy and safety of rezafungin versus caspofungin for the treatment of candidemia and invasive candidiasis in a China cohort of a double-blind, randomized, phase 3 trial (ReSTORE China)","author":"Huang","year":"2025","journal-title":"Mycoses"},{"key":"2025092508515641200_ofaf555-B31","doi-asserted-by":"crossref","first-page":"e0091623","DOI":"10.1128\/aac.00916-23","article-title":"Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasis","volume":"67","author":"Roepcke","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2025092508515641200_ofaf555-B32","doi-asserted-by":"crossref","first-page":"e0158423","DOI":"10.1128\/aac.01584-23","article-title":"Outcomes by Candida spp. in the ReSTORE phase 3 trial of rezafungin versus caspofungin for candidemia and\/or invasive candidiasis","volume":"68","author":"Locke","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2025092508515641200_ofaf555-B33","doi-asserted-by":"crossref","first-page":"106435","DOI":"10.1016\/j.jinf.2025.106435","article-title":"Rezafungin in special populations with candidaemia and\/or invasive candidiasis","volume":"90","author":"Cornely","year":"2025","journal-title":"J Infect"},{"key":"2025092508515641200_ofaf555-B34","author":"Fresenius Kabi"},{"key":"2025092508515641200_ofaf555-B35","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/13693786.2010.512300","article-title":"Early treatment of candidemia in adults: a review","volume":"49","author":"Ostrosky-Zeichner","year":"2011","journal-title":"Med Mycol"},{"key":"2025092508515641200_ofaf555-B36","doi-asserted-by":"crossref","first-page":"e01627-16","DOI":"10.1128\/AAC.01627-16","article-title":"Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults","volume":"61","author":"Sandison","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025092508515641200_ofaf555-B37","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S1473-3099(23)00627-8","article-title":"New antifungals development: rezafungin in candidiasis treatment","volume":"24","author":"Desnos-Ollivier","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025092508515641200_ofaf555-B38","doi-asserted-by":"crossref","first-page":"i33","DOI":"10.1093\/jac\/dkx447","article-title":"Overview of antifungal dosing in invasive candidiasis","volume":"73","author":"Pea","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2025092508515641200_ofaf555-B39","doi-asserted-by":"crossref","first-page":"e0143524","DOI":"10.1128\/aac.01435-24","article-title":"Population pharmacokinetics of caspofungin in critically ill patients receiving extracorporeal membrane oxygenation-an ASAP ECMO study","volume":"69","author":"Abdul-Aziz","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"2025092508515641200_ofaf555-B40","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s15010-024-02448-x","article-title":"Anidulafungin exposure and population pharmacokinetics in critically ill patients with invasive candidiasis","volume":"53","author":"Elkayal","year":"2024","journal-title":"Infection"},{"key":"2025092508515641200_ofaf555-B41","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.jval.2021.11.155","article-title":"POSC9 early response in the treatment of invasive Candida disease, length of stay on the intensive care unit and projected costs with once-weekly rezafungin antifungal therapy","volume":"25","author":"Bielicka","year":"2022","journal-title":"Value Health"},{"key":"2025092508515641200_ofaf555-B42","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/s13054-024-05152-2","article-title":"Length of hospital and intensive care unit stay in patients with invasive candidiasis and\/or candidemia treated with rezafungin: a pooled analysis of two randomised controlled trials","volume":"28","author":"Honore","year":"2024","journal-title":"Crit Care"},{"key":"2025092508515641200_ofaf555-B43","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.vhri.2019.07.002","article-title":"The economic burden of candidemia and invasive candidiasis: a systematic review","volume":"21","author":"Wan Ismail","year":"2020","journal-title":"Value Health Reg Issues"},{"key":"2025092508515641200_ofaf555-B44","doi-asserted-by":"crossref","first-page":"dlad079","DOI":"10.1093\/jacamr\/dlad079","article-title":"Health-economic modelling of cost savings due to the use of rezafungin based on a German cost-of-illness study of candidiasis","volume":"5","author":"Jeck","year":"2023","journal-title":"JAC Antimicrob Resist"},{"key":"2025092508515641200_ofaf555-B45","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1016\/j.jval.2023.09.599","article-title":"EE333 Cost-effectiveness of once-weekly rezafungin for the treatment of candidemia and invasive candidiasis in the UK","volume":"26","author":"Muszbek","year":"2023","journal-title":"Value Health"},{"key":"2025092508515641200_ofaf555-B46","doi-asserted-by":"crossref","first-page":"e0084221","DOI":"10.1128\/AAC.00842-21","article-title":"Population pharmacokinetics of rezafungin in patients with fungal infections","volume":"65","author":"Rubino","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2025092508515641200_ofaf555-B47","doi-asserted-by":"crossref","first-page":"R117","DOI":"10.1186\/cc13911","article-title":"Evaluation of simplified acute physiology score 3 performance: a systematic review of external validation studies","volume":"18","author":"Nassar","year":"2014","journal-title":"Crit Care"},{"key":"2025092508515641200_ofaf555-B48","doi-asserted-by":"crossref","first-page":"ofaf034","DOI":"10.1093\/ofid\/ofaf034","article-title":"Long-term safety and effectiveness of rezafungin treatment in candidemia and invasive candidiasis: results from an early access program in Italy and Germany","volume":"12","author":"Trapani","year":"2025","journal-title":"Open Forum Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaf555\/64265777\/ofaf555.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/9\/ofaf555\/64265777\/ofaf555.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/9\/ofaf555\/64265777\/ofaf555.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:52:11Z","timestamp":1758804731000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf555\/8253965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,8,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf555","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,8,29]]},"article-number":"ofaf555"}}